<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Infect Immun</journal-id>
      <journal-id journal-id-type="publisher-id">INFECT IMMUN</journal-id>
      <journal-title>Infection and Immunity</journal-title>
      <issn pub-type="ppub">0019-9567</issn>
      <issn pub-type="epub">1098-5522</issn>
      <publisher>
        <publisher-name>American Society for Microbiology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">10024548</article-id>
      <article-id pub-id-type="pmc">96434</article-id>
      <article-id pub-id-type="publisher-id">1049</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Microbial Immunity and Vaccines</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pathogenicity Island 2 Mutants of <italic>Salmonella typhimurium</italic> Are Efficient Carriers for Heterologous Antigens and Enable Modulation of Immune Responses</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Medina</surname>
            <given-names>Eva</given-names>
          </name>
          <xref ref-type="aff" rid="N0x9b45678.0x9a414f0">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paglia</surname>
            <given-names>Paola</given-names>
          </name>
          <xref ref-type="aff" rid="N0x9b45678.0x9a414f0">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nikolaus</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="N0x9b45678.0x9a414f0">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xFC;ller</surname>
            <given-names>Astrid</given-names>
          </name>
          <xref ref-type="aff" rid="N0x9b45678.0x9a414f0">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hensel</surname>
            <given-names>Michael</given-names>
          </name>
          <xref ref-type="aff" rid="N0x9b45678.0x9a414f0">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guzm&#xE1;n</surname>
            <given-names>Carlos A.</given-names>
          </name>
          <xref ref-type="aff" rid="N0x9b45678.0x9a414f0">1</xref>
          <xref ref-type="author-notes" rid="FN150">*</xref>
        </contrib>
      </contrib-group>
      <aff id="N0x9b45678.0x9a414f0"> Department of Microbial Pathogenicity and Vaccine Research, Division of Microbiology, GBF-National Research Centre for Biotechnology, D-38124 Braunschweig,<sup>1</sup> and  Lehrstuhl f&#xFC;r Bakteriologie, Max von Pettenkofer-Institut f&#xFC;r Hygiene und Medizinische Mikrobiologie, D-80336 Munich,<sup>3</sup> Germany, and  Experimental Immunotherapy and Gene Therapy Unit, Istituto Nazionale per Lo Studio e la Cura dei Tumori, I-20133 Milano, Italy<sup>2</sup></aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>McGhee</surname>
            <given-names>J. R.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn id="FN150">
          <label>*</label>
          <p>Corresponding author. Mailing address: Department of Microbial Pathogenicity and Vaccine Research, Division of Microbiology, GBF-National Research Centre for Biotechnology, Mascheroder Weg 1, D-38124 Braunschweig, Germany. Phone: 49-531-6181558. Fax: 49-531-6181411. E-mail: <email>cag@gbf.de</email>.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>1999</year>
      </pub-date>
      <volume>67</volume>
      <issue>3</issue>
      <fpage>1093</fpage>
      <lpage>1099</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>8</month>
          <year>1998</year>
        </date>
        <date date-type="rev-request">
          <day>20</day>
          <month>10</month>
          <year>1998</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>12</month>
          <year>1998</year>
        </date>
      </history>
      <copyright-statement>Copyright &#xA9; 1999, American Society for Microbiology</copyright-statement>
      <copyright-year>1999</copyright-year>
      <abstract>
        <p>The potential use as vaccine delivery system of <italic>Salmonella typhimurium</italic> strains harboring defined mutations in the <italic>sseC</italic> (HH104) and <italic>sseD</italic> (MvP101) genes, which encode putative effector proteins of the type III secretion system of <italic>Salmonella</italic> pathogenicity island 2, was evaluated and compared with that of the well-characterized <italic>aroA</italic> mutant strain SL7207 by using &#x3B2;-galactosidase (&#x3B2;-Gal) as a model antigen. When orally administered to immune-competent or gamma interferon-deficient (IFN-&#x3B3;<sup>&#x2212;/&#x2212;</sup>) BALB/c mice, both mutants were found to be highly attenuated (50% lethal dose, &gt;10<sup>9</sup> bacteria). Both strains were also able to efficiently colonize and persist in Peyer&#x2019;s patches. Immunization with HH104 and MvP101 triggered &#x3B2;-Gal-specific serum and mucosal antibody responses equivalent to or stronger than those observed in SL7207-immunized mice. Although immunoglobulin G2 (IgG2) serum antibodies were dominant in all groups, IgG1 was also significantly increased in mice vaccinated with MvP101 and SL7207. Comparable &#x3B2;-Gal-specific IgA and IgG antibodies were detected in intestinal lavages from mice immunized with the different strains. Antigen-specific CD4<sup>+</sup> T-helper cells were generated after vaccination with all vaccine prototypes; however, responses were significantly more efficient when HH104 and MvP101 were used (<italic>P</italic> &lt; 0.05). Significantly higher levels of IFN-&#x3B3; were produced by restimulated spleen cells from mice immunized with HH104 than from those vaccinated with the MvP101 or SL7207 derivatives (<italic>P</italic> &#x2264; 0.05). Interestingly, the three strains induced major histocompatibility complex class I-restricted CD8<sup>+</sup> cytotoxic T cells against &#x3B2;-Gal; however, cytotoxic T-lymphocyte responses were significantly stronger after immunization with HH104 (<italic>P</italic> &lt; 0.05). These novel <italic>S. typhimurium</italic> attenuated strains constitute promising delivery systems for vaccine antigens. The qualitative differences observed in the obtained responses with different carriers may be useful for those applications in which a targeted immunomodulation is required.</p>
      </abstract>
    </article-meta>
  </front>
</article>
</pmc-articleset>